Emerging drugs for the treatment of cutaneous T-cell lymphoma

References

• Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70(2):205.e1-16; quiz 221–2.
   Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785.
   PubMed Web of Science ®Google Scholar
• Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013;149(11):1295–1299.
   PubMed Web of Science ®Google Scholar
• Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch Dermatol. 2007;143(7):854–859.
   PubMedGoogle Scholar
• Campbell JJ, Clark RA, Watanabe R, et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767–771.
   PubMed Web of Science ®Google Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730–4739.
   PubMed Web of Science ®Google Scholar
• Choi J, Goh G, Walradt T, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011–1019.
   PubMed Web of Science ®Google Scholar
• Ralfkiaer U, Hagedorn PH, Bangsgaard N, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood. 2011;118(22):5891–5900.
   PubMed Web of Science ®Google Scholar
• Martinez-Escala ME, Choi J. Are microRNAs key to developing biomarkers for cutaneous T-cell lymphoma? J Invest Dermatol. 2018;138(9):1906–1908.
   PubMed Web of Science ®Google Scholar
• Shen X, Wang B, Li K, et al. MicroRNA signatures in diagnosis and prognosis of cutaneous T-cell lymphoma. J Invest Dermatol. 2018;138(9):2024–2032.
   PubMed Web of Science ®Google Scholar
• van der Weyden CA, Pileri SA, Feldman AL, et al. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017;7(9):e603–e603.
   PubMed Web of Science ®Google Scholar
• Edinger JT, Clark BZ, Pucevich BE, et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol. 2009;33(12):1860–1868.
   PubMed Web of Science ®Google Scholar
• Ferenczi K, Fuhlbrigge RC, Kupper TS, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119(6):1405–1410.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Leung S, Myskowski PL, et al. Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile. Cancer Immunol Res. 2018;6(8):900–909.
   PubMed Web of Science ®Google Scholar
• Zhang W, Huang Q, Xiao W, et al. Advances in anti-tumor treatments targeting the CD47/SIRPα axis. FronT Immunol. 2020;11(18).
   Google Scholar
• Thompson JA, Akilov O, Querfeld C, et al. A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides. J Clin Oncol. 2017;35(15_suppl):3101.
   Google Scholar
• Waldmann TA. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res. 2015;3(3):219–227.
   PubMed Web of Science ®Google Scholar
• Mishra A, La Perle KMD, Sullivan L, et al. Increased expression of IL-15 promotes cutaneous T-cell lymphomagenesis via the upregulation of histone deacetylases: evidence for successful preclinical targeting. Blood. 2013;122(21):1826.
   Google Scholar
• Wong HK, Mishra A, Hake T, et al. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol. 2011;155(2):150–166.
   PubMed Web of Science ®Google Scholar
• Netchiporouk E, Litvinov IV, Moreau L, et al. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle. 2014;13(21):3331–3335.
   PubMed Web of Science ®Google Scholar
• Vieyra-Garcia PA, Wei T, Naym DG, et al. STAT3/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides. Clin Cancer Res. 2016;22(13):3328–3339.
   PubMed Web of Science ®Google Scholar
• Geskin LJ, Viragova S, Stolz DB, et al. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015;125(18):2798–2805.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Rosen ST. Cutaneous T-cell lymphomas: mycosis fungoides and sezary syndrome-a guide for the practicing oncologist. Vitoria Australia: City of Hope National Medical Center Duarte, California Peter MacCallum Cancer Centre Melbourne; 2019.
   Google Scholar
• Khan S, Sawas A. Antibody-directed therapies: toward a durable and tolerable treatment platform for CTCL. Front Oncol. 2019;9(645). doi:https://doi.org/10.3389/fonc.2019.00645
   Google Scholar
• Bagot M, Porcu P, Marie-Cardine A, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019;20(8):1160–1170.
   PubMed Web of Science ®Google Scholar
• Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med. 2015;240(8):1087–1098.
   Web of Science ®Google Scholar
• Choe-Juliak C, Alexis KM, Schwarz S, et al. A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma or transformed mycosis fungoides: the REDIRECT study design and rationale. J Clin Oncol. 2020;38(15_suppl):3148.
   Web of Science ®Google Scholar
• Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014;70(2):223.e1-17; quiz 240–2.
   Web of Science ®Google Scholar
• Herrmann JJ, Roenigk HH, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol. 1995;33(2 Pt 1):234–242.
   PubMed Web of Science ®Google Scholar
• Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801–815.
   PubMed Web of Science ®Google Scholar
• Hoppe RT, Harrison C, Tavallaee M, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72(2):286–292.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Prince HM, Rosen ST. Cutaneous T-cell lymphomas: mycosis fungoides and sezary syndrome-a guide for the practicing oncologist. Victoria Australia: UBM Medica: City of Hope National Medical Center Duarte, California Peter MacCallum Cancer Centre Melbourne; 2017.
   Google Scholar
• Kohn EC, Steis RG, Sausville EA, et al. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome. J Clin Oncol. 1990;8(1):155–160.
   PubMed Web of Science ®Google Scholar
• Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456–2471.
   PubMed Web of Science ®Google Scholar
• Zic JA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther. 2003;16(4):337–346.
   PubMedGoogle Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–39.
   PubMed Web of Science ®Google Scholar
• Duvic M, Bates SE, Piekarz R, et al. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2018;59(4):880–887.
   PubMed Web of Science ®Google Scholar
• Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. Onco Targets Ther. 2019;12:1085–1094.
   PubMed Web of Science ®Google Scholar
• Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566.
   PubMed Web of Science ®Google Scholar
• Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16(5):1520–1531.
   PubMed Web of Science ®Google Scholar
• Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–1204.
   PubMed Web of Science ®Google Scholar
• Oka T, Miyagaki T. Novel and future therapeutic drugs for advanced mycosis fungoides and Sézary syndrome. Front Med. 2019;6:116.
   PubMed Web of Science ®Google Scholar
• Trum NA, Zain J, Martinez XU, et al. Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series. Br J Dermatol. 2022;186:153–166.
   PubMed Web of Science ®Google Scholar
• Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–3758.
   PubMed Web of Science ®Google Scholar
• Deng C, Pan B, O’Connor OA. Brentuximab vedotin. Clin Cancer Res. 2013;19(1):22–27.
   PubMed Web of Science ®Google Scholar
• Lai P, Wang Y. Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials. Cancer Biol Med. 2021;18(1):34–51.
   PubMed Web of Science ®Google Scholar
• Kopp KL, Ralfkiaer U, Mette Gjerdrum L, et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle. 2013;12(12):1939–1947.
   PubMed Web of Science ®Google Scholar
• Gluud M, Willerslev-Olsen A, Gjerdrum LMR, et al. MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas. Cancers (Basel). 2020;12:1229.
   Web of Science ®Google Scholar
• Querfeld C, Estephan R, Kil SH, et al. The regulation of PD-L1 expression by miRNAs in cutaneous T-cell lymphoma. Eur J Cancer. 2018;101:S9.
   Web of Science ®Google Scholar
• Han Z, Estephan RJ, and Wu X, et al. MiRNA regulation of T cell exhaustion in cutaneous T cell lymphoma. J Investig Dermatol. 2021;142(3):603–612.
   Google Scholar
• Querfeld C, Foss FM, Pinter-Brown LC, et al. Phase 1 study of the safety and efficacy of MRG-106, a synthetic inhibitor of microRNA-155, in CTCL patients. Blood. 2017;130(Suppl_1):820.
   Google Scholar
• Querfeld C, Pacheco T, Foss FM, et al. Preliminary results of a phase 1 trial evaluating MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, in patients with CTCL. Blood. 2016;128(22):1829.
   PubMed Web of Science ®Google Scholar
• Khodadoust M, Rook AH, Porcu P, et al. Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and sezary syndrome: clinical efficacy in a citn multicenter phase 2 study. Blood. 2016;128(22):181.
   Google Scholar
• Jiang Y, Chen M, Nie H, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–1122.
   PubMed Web of Science ®Google Scholar
• Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and sézary syndrome: a multicenter phase II study. J Clin Oncol. 2020;38(1):20–28.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Wu X, Stiller T, et al. Phase 1 results of anti-PD-ligand 1 (durvalumab) & lenalidomide in patients with cutaneous T cell lymphoma and correlation with programmed death ligand 1 expression and gene expression profile. Blood. 2019;134(Supplement_1):4024.
   Google Scholar
• Querfeld C, Zain JM, Wakefield DL, et al. Phase 1/2 trial of durvalumab and lenalidomide in patients with cutaneous T cell lymphoma (CTCL): preliminary results of phase I results and correlative studies. Blood. 2018;132(Supplement 1):2931.
   Google Scholar
• Querfeld C, Rosen ST, Guitart J, et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood. 2014;123(8):1159–1166.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Thompson J, Taylor M, et al. A single direct intratumoral injection of TTI-621 (SIRPαFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and sézary syndrome: preliminary findings employing an immune checkpoint inhibitor blocking the CD47 do not eat. Signal Blood. 2017;130(Supplement 1):4076.
   Google Scholar
• Querfeld C, Thompson JA, Taylor MH, et al. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sezary syndrome: a multicentre, phase 1 study. Lancet Haematol. 2021;8(11):e808–e817.
   PubMed Web of Science ®Google Scholar
• Querfeld C, William BM, Sokol L, et al. Co-inhibition of IL-2, IL-9, IL-15 by the novel immunomodulator Bnz-1, provides clinical efficacy in patients with refractory cutaneous T cell lymphoma in a phase 1/2 clinical trial. Blood. 2020;136:37.
   Web of Science ®Google Scholar
• Bagot M, Porcu P, Ram-Wolff C, et al. First-in-human, multicenter phase I study of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas: preliminary safety, exploratory and clinical activity results. Blood. 2016;128(22):1826.
   Web of Science ®Google Scholar
• Katsuya H, Cook LBM, Rowan AG, et al. Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma. Biomark Res. 2018;6:24.
   PubMed Web of Science ®Google Scholar
• Huen A, Haverkos BM, Zain J, et al. Phase I/Ib study of tenalisib (RP6530), a dual PI3K δ/γ inhibitor in patients with relapsed/refractory T-cell lymphoma. Cancers (Basel). 2020;12(8):2293.
   Web of Science ®Google Scholar
• Horwitz SM, Feldman TA, Hess BT, et al. A phase 2 study of the dual SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Blood. 2019;134(Supplement_1):466.
   Google Scholar
• Duvic M, Guitart J, Huen A, et al. 607 Anti-pruritic properties of remetinostat (SHAPE), a topical histone deacetylase inhibitor (HDACi); data from a randomized phase 2 study in patients with stage IA- IIA mycosis fungoides. J Investig Dermatol. 2018;138(5):S103.
   Web of Science ®Google Scholar
• Rook AH, Wood GS, Duvic M, et al. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol. 2010;63(6):984–990.
   PubMed Web of Science ®Google Scholar
• Seto AG, Beatty X, Lynch JM, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 2018;183(3):428–444.
   PubMed Web of Science ®Google Scholar
• Scarfò I, Frigault MJ, Maus MV. CAR-based approaches to cutaneous T-cell lymphoma. Front Oncol. 2019;9:259.
   PubMed Web of Science ®Google Scholar